J&J-100US

Appln. No.: 10/629,308

Amendment Dated March 22, 2010

Reply to Final Office Action of January 21, 2010

Amendments to the Claims:

This list of claims replaces all prior versions and lists of claims in the application:

1. (Previously Presented) A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients consisting essentially of:

7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;

2% to 4% (w/v) polyethylene glycol;

less than 1% (w/v) lipid;

0.5 to 2% (w/v) propylene glycol;

an antimicrobial agent; and,

a pH modifier.

wherein the composition is clear to the naked eye.

- 2 5. (Canceled)
- (Previously Presented) The composition of Claim 1, wherein said polyethylene glycol is polyethylene glycol 400.
- 7. (Canceled)
- 8. (Previously Presented) The composition of Claim 1, wherein:
- a) said composition has a particle size diameter of between 25 and 200 nm;
- b) said composition has a particle size diameter of between 50 and 100 nm; or
- c) said composition forms particles of similar particle size.
- 9. (Previously Presented) The composition of Claim 1, wherein:
- a) said composition does not support microbial growth; or
- b) said composition is microbicidal.
- 10.-24. (Canceled)

Appln. No.: 10/629,308

Amendment Dated March 22, 2010

Reply to Final Office Action of January 21, 2010

(Currently Amended) A sterile aqueous pharmaceutical composition for parenteral 25. administration of propofol, said composition consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients consisting essentially of:

7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;

2% to 4% (w/v) polyethylene glycol;

0.5% to 1% (w/v) propylene glycol;

an antimicrobial agent;

a pH modifier;

and less than 1% (w/v) lipid, wherein the composition is clear to the naked eye.

- 26. (Previously Presented) The composition of Claim 25, wherein said excipients consist essentially of 8% (w/v) Poloxamer 188; 3% (w/v) polyethylene glycol 400; 1% (w/v) propylene glycol, an antimicrobial agent, and a pH modifier.
- 27. (Previously Presented) The composition of Claim 1, wherein said composition is stored in a container having a means for dispensing the composition.

28-29. (Canceled)